TRISENOX Concentrate for solution for infusion Ref.[6218] Active ingredients: Arsenic trioxide

Source: European Medicines Agency (EU)  Revision Year: 2018  Publisher: Teva B.V., Swensweg 5, 2031 GA, Haarlem, Netherlands

Product name and form

TRISENOX 1 mg/ml concentrate for solution for infusion.

TRISENOX 2 mg/ml concentrate for solution for infusion.

Pharmaceutical Form

Concentrate for solution for infusion (sterile concentrate).

Clear, colourless, aqueous solution.

Qualitative and quantitative composition

TRISENOX 1 mg/ml concentrate for solution for infusion:

Each ml of concentrate contains 1 mg of arsenic trioxide.

Each ampoule of 10 ml contains 10 mg of arsenic trioxide.

TRISENOX 2 mg/ml concentrate for solution for infusion:

Each ml of concentrate contains 2 mg of arsenic trioxide.

Each vial of 6 ml contains 12 mg of arsenic trioxide.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Arsenic trioxide

Arsenic trioxide causes morphological changes and deoxyribonucleic acid (DNA) fragmentation characteristic of apoptosis in NB4 human promyelocytic leukaemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR alpha.

List of Excipients

Sodium hydroxide
Hydrochloric acid (for pH adjustment)
Water for injections

Pack sizes and marketing

TRISENOX 1 mg/ml concentrate for solution for infusion: Type I borosilicate glass ampoule containing 10 ml of concentrate. Each pack contains 10 ampoules.

TRISENOX 2 mg/ml concentrate for solution for infusion: 6 ml concentrate in a clear, Type I borosilicate glass vial with a chlorobutyl rubber stopper (FluroTec coated plug) and an aluminium crimp cap with a plastic flip-top button. Each pack contains 10 vials.

Marketing authorization holder

Teva B.V., Swensweg 5, 2031 GA, Haarlem, Netherlands

Marketing authorization dates and numbers

TRISENOX 1 mg/ml concentrate for solution for infusion: EU/1/02/204/001
TRISENOX 2 mg/ml concentrate for solution for infusion: EU/1/02/204/002

Date of first authorisation: 05 March 2002
Date of latest renewal: 05 March 2007

Drugs

Drug Countries
TRISENOX Austria, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Turkey, United Kingdom, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.